Drug Profile
HT 61
Alternative Names: HT-61; HY 50ALatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Helperby Therapeutics
- Class Antibacterials; Quinolones; Small molecules
- Mechanism of Action Cell membrane modulators; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 28 Aug 2019 Discontinued - Phase-II for Staphylococcal infections (Combination therapy) in United Kingdom (Topical)
- 28 Aug 2019 Discontinued - Phase-III for Staphylococcal infections (Combination therapy) in United Kingdom (Topical)
- 08 Feb 2019 Helperby Therapeutics terminates a phase III trial in Staphylococcal infections (Combination therapy) in United Kingdom (Topical, gel) (EudraCT2009-017398-39)